From: The trials methodological research agenda: results from a priority setting exercise
Round 2 | Round 3 | Rank | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Topic | Number of responders | 1 to 3 | Scores* 4 to 6 | 7 to 9 | Consensus? | Number of responders | 1 to 3 | Scores* 4 to 6 | 7 to 9 | Consensus? | |
% responders | % responders | ||||||||||
Surgical trials | 30 | 10.0 | 43.3 | 46.7 | 23 | 8.7 | 30.4 | 60.9 | 1 | ||
Use of routine data | 29 | 17.2 | 41.4 | 41.4 | 23 | 8.7 | 39.1 | 52.2 | 2 | ||
Using previous evidence to inform design | 31 | 25.8 | 41.9 | 32.3 | 23 | 13.0 | 43.5 | 43.5 | 3 | ||
Strategies of trial management | 30 | 23.3 | 43.3 | 33.3 | 23 | 17.4 | 47.8 | 34.8 | 4 | ||
Assessing potential for and effect of attrition bias | 30 | 10.0 | 63.3 | 26.7 | 23 | 4.3 | 65.2 | 30.4 | 5 | ||
Non-drug trials | 30 | 23.3 | 46.7 | 30.0 | 22 | 13.6 | 59.1 | 27.3 | 6 | ||
QALYs for children | 31 | 29.0 | 41.9 | 29.0 | 23 | 21.7 | 52.2 | 26.1 | 7 | ||
Calculating the target difference | 31 | 22.6 | 58.1 | 19.4 | 23 | 13.0 | 65.2 | 21.7 | 8 | ||
Patient and public involvement | 30 | 26.7 | 60.0 | 13.3 | 23 | 26.1 | 52.2 | 21.7 | 9 | ||
Strategies for adverse event reporting | 30 | 30.0 | 50.0 | 20.0 | 23 | 21.7 | 60.9 | 17.4 | 10 | ||
Designs in rare diseases | 31 | 12.9 | 64.5 | 22.6 | 23 | 13.0 | 73.9 | 13.0 | 11 | ||
Studies of diagnosis | 29 | 31.0 | 48.3 | 20.7 | 23 | 39.1 | 47.8 | 13.0 | 12 | ||
Methods to adjust for baseline imbalance | 31 | 32.3 | 51.6 | 16.1 | 23 | 47.8 | 39.1 | 13.0 | 13 | ||
Data modelling | 30 | 26.7 | 56.7 | 16.7 | 22 | 31.8 | 59.1 | 9.1 | 14 | ||
Phase IV studies | 30 | 40.0 | 43.3 | 16.7 | 22 | 54.5 | 36.4 | 9.1 | 15 | ||
Prevention studies | 30 | 20.0 | 60.0 | 20.0 | 23 | 17.4 | 73.9 | 8.7 | 16 | ||
Trial reporting issues | 28 | 39.3 | 50.0 | 10.7 | 23 | 26.1 | 65.2 | 8.7 | 17 | ||
Dose–response studies | 30 | 30.0 | 50.0 | 20.0 | 23 | 34.8 | 56.5 | 8.7 | 18 | ||
Methods to measure pain | 31 | 41.9 | 48.4 | 9.7 | 23 | 47.8 | 43.5 | 8.7 | 19 | ||
Low carbon trials | 30 | 70.0 | 23.3 | 6.7 | out | 23 | 78.3 | 13.0 | 8.7 | out | 20 |
Eligibility criteria | 31 | 58.1 | 35.5 | 6.5 | 22 | 63.6 | 31.8 | 4.5 | 21 | ||
Patient preference designs/issues | 29 | 20.7 | 69.0 | 10.3 | 23 | 21.7 | 73.9 | 4.3 | 22 | ||
Design of paediatric investigation plans | 30 | 46.7 | 43.3 | 10.0 | 23 | 56.5 | 39.1 | 4.3 | 23 | ||
Conflict of interest | 31 | 51.6 | 48.4 | 0.0 | 23 | 65.2 | 30.4 | 4.3 | 24 | ||
Database trials | 30 | 33.3 | 63.3 | 3.3 | 23 | 26.1 | 73.9 | 0.0 | 25 | ||
Crossover trials | 31 | 32.3 | 64.5 | 3.2 | 23 | 39.1 | 60.9 | 0.0 | 26 | ||
Incorporating multiple disease/multiple treatment types into single protocols | 30 | 36.7 | 50.0 | 13.3 | 22 | 59.1 | 40.9 | 0.0 | 27 |